Biomarker Clinical Phase Outsourcing Services Market Analysis and Forecast 2023-2030

The global biomarker clinical phase outsourcing services market is anticipated to grow at a considerable CAGR of 21.3% during the forecast period (2023-2030). The increasing utilization of biomarkers for several chronic diseases has significantly propelled the market growth. The diverse range of biomarkers and their applications in monitoring and diagnosing several disorders. Advancements in biomarker technology are increasing the potentials for more personalized treatment, accurate and early disease detection, and improved patient outcomes. Some of the primary biomarkers that are significantly used in several clinical indications, such as-

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/biomarker-clinical-phase-outsourcing-services-market

•             CA-125: CA-125 is a biomarker used in the diagnosis and monitoring of ovarian cancer, which screening of high-risk women with ovaries despite its limited sensitivity and specificity. Recent findings suggest that CA125 might also serve as a predictive marker for pre-invasive OC.

•             Prostate-Specific Antigen (PSA): PSA is a biomarker used in the screening & monitoring of prostate cancer. The PSA test measures the level of PSA in the blood. In 1994, FDA approved the PSA test to be used in conjunction with a digital rectal exam (DRE) to aid in the detection of prostate cancer in men 50 years and older. 

•             HER2/neu: HER2/neu is a biomarker used to recognize breast cancer patients who may benefit from targeted therapies. HER2/neu on cancer cells is measured in 2 ways. Immunohistochemistry (IHC) testing checks for this protein on the surface of cancer cells. Fluorescence in situ hybridization (FISH) tests for the genes that direct the cell to make HER2/neu protein. 

•             S100B: S100B is a biomarker utilized in traumatic brain injury (TBI) monitoring and diagnosis. S100b is specifically found in the cytoplasm and nucleus, and less than 1% of this protein is secreted in a regulated fashion. Elevated CSF S100b levels after severe brain injury may reflect ongoing structural damage and cell death.

•             BNP (B-type natriuretic peptide): BNP is a biomarker used for diagnosing heart failure and assessing its severity. B-type natriuretic peptide (BNP) is a member of a family of natriuretic peptides (NP) that include atrial natriuretic peptide (ANP), C-type natriuretic peptide, D-type natriuretic peptide, and urodilatin.

Market Coverage

•             The market number available for – 2022-2030

•             Base year- 2022

•             Forecast period- 2023-2030

•             Segment Covered- 

o             By Type

o             By Therapeutic Area

o             By End-Use

•             Regions Covered-

o             North America

o             Europe

o             Asia-Pacific

o             Rest of the World

•             Competitive Landscape- includes Celerion, Fujirebio Europe NV, ICON plc, and Parexel International Corp., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Biomarker Clinical Phase Outsourcing Services Market Report Segment

By Type

• Predictive Biomarkers
• Prognostic Biomarkers
• Safety Biomarkers
• Surrogate Endpoints

By Therapeutic Area

• Oncology
• Cardiology
• Neurology
• Autoimmune Diseases

By End-Use

• Pharmaceutical Companies
• Biotechnology Companies

A full report of Biomarker Clinical Phase Outsourcing Services Market available @ https://www.omrglobal.com/industry-reports/biomarker-clinical-phase-outsourcing-services-market

Biomarker Clinical Phase Outsourcing Services Market Report Segment by Region

North America          

• United States
• Canada

Europe

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific   

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Middle East & Africa
• Latin America

Company Profiles

• Charles River Laboratories International, Inc.
• Eurofins Scientific corp.
• GenScript ProBio Biotech Corp.
• GHO Capital Partners LLP
• Laboratory Corporation of America® Holdings
• NorthEast BioAnalytical Laboratories LLC
• Proteome Sciences plc
• Thermo Fisher Scientific Inc.
• WuXi AppTec Co., Ltd.
• Zymewire (Division of Lumerate Inc.)

Reasons to Buying From us –

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

Media Contact:

Contact Person: Mr. Anurag Tiwari

Email: anurag@omrglobal.com

Contact no: +91 780-304-0404

Company Name: Orion Market Research

Article source: https://article-realm.com/article/Health-Fitness/59030-Biomarker-Clinical-Phase-Outsourcing-Services-Market-Analysis-and-Forecast-2023-2030.html